Castle Biosciences CSTL Business Segments — Long-lived assets, expenditure

Similar metrics at other companies

MLMReportable Segments — Segment Expenditure Addition To Long Lived Assets

$2.51B+1,801%

LLYReportable Segment — Expenditures for long-lived assets

$2.91B+46.4%

VGN

VGNTReportable Segment — Segment, Expenditure, Addition to Long-Lived Assets

$66M+78.4%

CATOReportable Segments Credit — Segment Expenditure Addition To Long Lived Assets

$0—

CATOReportable Segments Retail — Segment Expenditure Addition To Long Lived Assets

$940.75K-52.2%

NUSHong Kong Taiwan — Segment Expenditure Addition To Long Lived Assets

$15K-71.2%

FAQ

What is Castle Biosciences's business segments — long-lived assets, expenditure?

Castle Biosciences (CSTL) reported business segments — long-lived assets, expenditure of $5.2M in Q1 2026.

How has Castle Biosciences's business segments — long-lived assets, expenditure changed year-over-year?

Castle Biosciences's business segments — long-lived assets, expenditure decreased by 8.8% year-over-year, from $5.7M to $5.2M.

What is the long-term trend for Castle Biosciences's business segments — long-lived assets, expenditure?

Over 3 years (2022 to 2025), Castle Biosciences's business segments — long-lived assets, expenditure has grown at a 86.1% compound annual growth rate (CAGR), from $7M to $45.1M.

What does business segments — long-lived assets, expenditure mean?

This represents the capital investment made by the segment to acquire or upgrade physical and long-term assets necessary for business operations. It indicates the segment's commitment to scaling its diagnostic capabilities and long-term growth infrastructure.